Journal of Clinical Pediatrics >
A preliminary study on characteristics of visual evoked potentials in children with myelin oligodendrocyte glycoprotein immunoglobulin G associated disorders in the acute phase
Received date: 2021-08-30
Online published: 2022-04-07
Jinxiao CHEN , Jing SUN , Wenmin YANG , Xiaoyue WANG , Xin WANG , Jian YANG . A preliminary study on characteristics of visual evoked potentials in children with myelin oligodendrocyte glycoprotein immunoglobulin G associated disorders in the acute phase[J]. Journal of Clinical Pediatrics, 2022 , 40(4) : 284 -289 . DOI: 10.12372/jcp.2022.21e1251
[1] | Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease[J]. Nat Rev Neurol, 2019, 15(2):89-102. |
[2] | de Mol CL, Wong Y, van Pelt ED, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults[J]. Mult Scler, 2020, 26(7):806-814. |
[3] | Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing[J]. J Neuroinflammation, 2018, 15(1):134. |
[4] | 中国免疫学会神经免疫分会. 抗髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体相关疾病诊断和治疗中国专家共识[J]. 中国神经免疫学和神经病学杂志, 2020, 27(2):86-95. |
[5] | Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, et al. Clinical and MRI phenotype of children with MOG antibodies[J]. Mult Scler, 2016, 22(2):174-184. |
[6] | Waters P, Fadda G, Woodhall M, et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes[J]. JAMA Neurol, 2020, 77(1):82-93. |
[7] | Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study[J]. Brain, 2017, 140(12):3128-3138. |
[8] | Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination[J]. J Neurol Neurosurg Psychiatry, 2018, 89(2):127-137. |
[9] | Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions[J]. Mult Scler, 2013, 19(10):1261-1267. |
[10] | 中华医学会眼科学分会神经眼科学组. 视神经炎诊断和治疗专家共识(2014年)[J]. 中华眼科杂志, 2014, (6):459-463. |
[11] | Peschl P, Bradl M, Höftberger R, et al. Myelin oligo-dendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases[J]. Front Immunol, 2017, 8:529. |
[12] | Duignan S, Wright S, Rossor T, et al. Myelin oligo-dendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes[J]. Dev Med Child Neurol, 2018, 60(9):958-962. |
[13] | 潘映辐. 临床诱发电位学 [M]. 2版. 北京: 人民卫生出版社, 2000. |
[14] | Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome[J]. J Neuroinflammation, 2016, 13(1):280. |
[15] | Salama S, Khan M, Levy M, et al. Radiological cha-racteristics of myelin oligodendrocyte glycoprotein antibody disease[J]. Mult Scler Relat Disord, 2019, 29:15-22. |
[16] | Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis[J]. Mult Scler, 2016, 22(4):470-482. |
[17] | Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome[J]. Neurology, 2017, 89(9):900-908. |
[18] | Tea F, Lopez JA, Ramanathan S, et al. Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination[J]. Acta Neuropathol Commun, 2019, 7(1):145. |
[19] | Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin[J]. J Neuroinflammation, 2016, 13(1):279. |
[20] | Cobo-Calvo A, Sepúlveda M, D'Indy H, et al. Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults[J]. J Neurol, 2019, 266(4):806-815. |
/
〈 |
|
〉 |